All In Biotech

NDA 018891 · Lavipharm

Catapres-Tts-3

Clonidine · Transdermal · Central alpha-2 Adrenergic Agonist

Last checked: Nov 20, 2026Latest source record: Dec 4, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1984

Oct 10, 1984

Approved uses

1

Original approval plus efficacy supplements

Registered trials

276

54 Phase 3, 19 recruiting

FAERS reports

2,134

564 serious, 61 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 8, 2026.

INDICATIONS AND USAGE Clonidine transdermal system is indicated in the treatment of hypertension. It may be employed alone or concomitantly with other antihypertensive agents.

Mechanism: System Structure and Components Clonidine Transdermal System, USP is a multi-layered film, 0.2 mm thick, containing clonidine as the active agent. The system areas are 3.5 cm 2 (Clonidine Transdermal System USP, 0.1 mg/day), 7.0 cm 2 (Clonidine Transdermal System USP, 0.2 mg/day) and 10.5 cm 2 (Clonidine Transdermal System USP, 0.3 mg/day) and the amount of drug released is directly proportional to the area (see Release Rate Concept ). The composition per unit area is the same for all three doses. Proceeding from the visible surface towards the surface attached to the skin, there are four...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 10, 1984 Original approval · Type 3 - New Dosage Form
3 products under this application
  • CATAPRES-TTS-3 · CLONIDINE 0.3MG/24HR · SYSTEM, TRANSDERMAL · Prescription · TE AB
  • CATAPRES-TTS-1 · CLONIDINE 0.1MG/24HR · SYSTEM, TRANSDERMAL · Prescription · TE AB
  • CATAPRES-TTS-2 · CLONIDINE 0.2MG/24HR · SYSTEM, TRANSDERMAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Clonidine" as an intervention, any sponsor and status, largest first.

All 276 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • application site pruritus347
  • application site erythema304
  • drug ineffective280
  • blood pressure increased254
  • application site rash198
  • product adhesion issue187
  • hypertension145
  • application site irritation123
  • wrong technique in product usage process100
  • headache96
  • application site vesicles83
  • blood pressure inadequately controlled83

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200446
200557
200652
2007157
2008290
2009249
2010170
201195
201270
201317
201444
201554
201668
2017103
201881
2019110
202073
202183
202252
202362
202435
202566
2026100

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,240 on PubMed

Sponsor: Lavipharm · Also marketed as Catapres-Tts-1, Catapres-Tts-2

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.